Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics
- PMID: 20107143
- DOI: 10.3945/jn.109.113753
Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics
Abstract
The rationale for the use of probiotics in the management of infectious diseases is supported by their potential to influence and stabilize the composition of gut microbiota, enhance colonization resistance, and modulate immune function parameters. A literature review was conducted to determine the efficacy of using probiotics in selected infections: 1) infectious diarrhea in infants and children, 2) traveler's diarrhea, 3) necrotizing enterocolitis in infants, 4) Helicobacter pylori infection, 5) respiratory tract infections in adults and children, 6) ear, nose, and throat infections, and 7) infectious complications in surgical and critically ill patients. The different types of infections that have been subject to clinical studies with different probiotics obviously prevent any generic conclusions. Furthermore, the lack of consistency among studies focusing on 1 specific infection, in study design, applied probiotic strains, outcome parameters, and study population, along with the still limited number of studies, preclude clear and definite conclusions on the efficacy of probiotics and illustrate the need for better-aligned study designs and methodology. Exceptions were the management of infectious diarrhea in infants and traveler's diarrhea, antibiotic-associated diarrhea, and necrotizing enterocolitis. Sufficient consistent data exist for these applications to conclude that certain probiotics, under certain conditions, and in certain target populations, are beneficial in reducing the risk of infection. In addition, some evidence exists, although conclusions are premature, for the management of Helicobacter pylori infection and possible reduction of treatment side effects. Certain probiotics may also reduce the risk of various symptoms of respiratory tract infections in adults and children, including ear, nose, and throat infections, although data are currently far too limited to distill any clinical recommendations in this area. Positive but also negative results have been obtained in prevention of infectious complications in surgical and critically ill patients. For future studies it is recommended that researchers provide adequate power, identify pathogens, and report both clinical outcomes and immune biomarkers relating to putative underlying mechanisms.
Similar articles
-
Use of probiotics in pediatric infectious diseases.Expert Rev Anti Infect Ther. 2015;13(12):1517-35. doi: 10.1586/14787210.2015.1096775. Epub 2015 Oct 23. Expert Rev Anti Infect Ther. 2015. PMID: 26496433 Review.
-
A meta-analysis of probiotic efficacy for gastrointestinal diseases.PLoS One. 2012;7(4):e34938. doi: 10.1371/journal.pone.0034938. Epub 2012 Apr 18. PLoS One. 2012. PMID: 22529959 Free PMC article.
-
The therapeutic effect of probiotic bacteria on gastrointestinal diseases.Adv Clin Exp Med. 2013 Sep-Oct;22(5):759-66. Adv Clin Exp Med. 2013. PMID: 24285463 Review.
-
When to use probiotics in luminal gastrointestinal disorders?Curr Opin Clin Nutr Metab Care. 2020 Sep;23(5):336-343. doi: 10.1097/MCO.0000000000000674. Curr Opin Clin Nutr Metab Care. 2020. PMID: 32657791 Review.
-
Probiotics for Gastrointestinal Conditions: A Summary of the Evidence.Am Fam Physician. 2017 Aug 1;96(3):170-178. Am Fam Physician. 2017. PMID: 28762696 Review.
Cited by
-
The Gut-CNS Axis in Multiple Sclerosis.Trends Neurosci. 2020 Aug;43(8):622-634. doi: 10.1016/j.tins.2020.06.002. Epub 2020 Jul 7. Trends Neurosci. 2020. PMID: 32650957 Free PMC article. Review.
-
Indication for Co-evolution of Lactobacillus johnsonii with its hosts.BMC Microbiol. 2012 Jul 25;12:149. doi: 10.1186/1471-2180-12-149. BMC Microbiol. 2012. PMID: 22827843 Free PMC article.
-
Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial.Am J Respir Crit Care Med. 2010 Oct 15;182(8):1058-64. doi: 10.1164/rccm.200912-1853OC. Epub 2010 Jun 3. Am J Respir Crit Care Med. 2010. PMID: 20522788 Free PMC article. Clinical Trial.
-
Engineered Akkermansia muciniphila: A promising agent against diseases (Review).Exp Ther Med. 2020 Dec;20(6):285. doi: 10.3892/etm.2020.9415. Epub 2020 Oct 29. Exp Ther Med. 2020. PMID: 33209129 Free PMC article. Review.
-
Antibiotics, microbiota, and immune defense.Trends Immunol. 2012 Sep;33(9):459-66. doi: 10.1016/j.it.2012.05.003. Epub 2012 Jun 5. Trends Immunol. 2012. PMID: 22677185 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical